1. Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
- Author
-
Xin Li, Robert S. Hodges, Kenza Mamouni, Hong Yan Liu, Lajos Gera, Rui Zhao, Alira Danaher, Lijuan Bai, Nicholas Cook, Xiaowei Ma, Omer Kucuk, Yang Yang, and Daqing Wu
- Subjects
Male ,IGF-1R, insulin-like growth factor-1 receptor ,Cancer Research ,BmSimob, 4-[(butyldimethylsilyl)methoxy]-benzoyl ,medicine.medical_treatment ,Preclinical studies ,AMDP(OEt)4, 1-aminomethylenedisphosphonic acid tetraethyl ester amide residue ,Bip, β-(4-biphenylyl)alanine residue ,Drug resistance ,Mice ,Prostate cancer ,LBD, ligand-binding domain ,Organosilicon Compounds ,RC254-282 ,Original Research ,Atmp, 4-amino-2,2,6,6-tetramethylpiperidine amide residue ,PSA, prostate-specific antigen ,CRPC, castration-resistant prostate cancer ,PROTAC, proteolysis-targeting chimaera ,PyBOP, benzotriazol-1-yloxytripyrrolidinophophonium hexafluorophosphate ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,KIF15, Kinesin family member 15 ,Small-molecule therapy ,MSipob, 4-[3-(trimethylsilyl)propoxy]-benzoyl ,Prostatic Neoplasms, Castration-Resistant ,COX-2, cyclooxygenase-2 ,AR-V7, AR variant 7 ,medicine.symptom ,Chemoresistance ,GRP78, glucose-regulated protein 78kD ,IHC, immunohistochemistry ,PCa, prostate cancer ,SIAH2, siah E3 ubiquitin protein ligase 2 ,Antineoplastic Agents ,HSP90, heat shock protein 90 ,Cell Line ,Silicon-containing compounds ,TFA, trifluoroacetic acid ,HSP27, heat shock protein 27 ,In vivo ,Survivin ,medicine ,BOP, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate ,Animals ,Humans ,NTD, N-terminal domain ,ADT, androgen deprivation therapy ,Chemotherapy ,business.industry ,OC2Y, O-2,6-dichlorobenzyl-tyrosine residue ,medicine.disease ,Xenograft Model Antitumor Assays ,Androgen receptor ,Mechanism of action ,Drug Resistance, Neoplasm ,Apoptosis ,Cancer research ,Castration-resistance ,AR, androgen receptor ,DIEA, N,N-diisopropylethylamine ,Drug Screening Assays, Antitumor ,business - Abstract
A major challenge to the treatment of advanced prostate cancer (PCa) is the development of resistance to androgen-deprivation therapy (ADT) and chemotherapy. It is imperative to discover effective therapies to overcome drug resistance and improve clinical outcomes. We have developed a novel class of silicon-containing compounds and evaluated the anticancer activities and mechanism of action using cellular and animal models of drug-resistant PCa. Five organosilicon compounds were evaluated for their anticancer activities in the NCI-60 panel and established drug-resistant PCa cell lines. GH1504 exhibited potent in vitro cytotoxicity in a broad spectrum of human cancer cells, including PCa cells refractory to ADT and chemotherapy. Molecular studies identified several potential targets of GH1504, most notably androgen receptor (AR), AR variant 7 (AR-v7) and survivin. Mechanistically, GH1504 may promote the protein turnover of AR, AR-v7 and survivin, thereby inducing apoptosis in ADT-resistant and chemoresistant PCa cells. Animal studies demonstrated that GH1504 effectively inhibited the in vivo growth of ADT-resistant CWR22Rv1 and chemoresistant C4-2B-TaxR xenografts in subcutaneous and intraosseous models. These preclinical results indicated that GH1504 is a promising lead that can be further developed as a novel therapy for drug-resistant PCa.
- Published
- 2021
- Full Text
- View/download PDF